Moe Alsumidaie

Marci Macpherson, executive director, quality assurance and compliance at Ionis Pharmaceuticals, discusses her perspectives on inspection readiness.

Dr. Pratik Darji, Head of Progressive Clinical Research Solutions in Gujarat, India discusses the state of clinical trials in the country.

Richard Williams, PhD, chief medical officer at Kinnate Biopharma Inc. discusses clinical trial strategies and challenges.

Sharon Reinhard, VP of quality at AVROBIO, discusses a qualitative perspective on the CRA shortage topic.

Jill Pellegrino, vice president of recruitment and RWE at CVS Health® Clinical Trial Services discusses the infrastructure of recruiting patients in pharmacy settings and why CVS Health has entered into the world of clinical trials.

Sheri Kuss, clinical quality group lead at Pfizer, discusses the new "culture of quality" in clinical trials.

Robert Foster, CEO of Hepion Pharmaceuticals, discusses strategies for being competitive in the current economic environment.

Barbara Lopez Kunz, president, and global chief executive at DIA, discusses key themes on the current state of the clinical trials industry and its future.

Danielle Mitchell, Founder of Black Women in Clinical Research, discusses how her foundation bridges the gap between minority professionals and clinical trials.

While DCTs continue to take hold on industry, questions remain.

Risk-reward tolerance standing in way of underperforming trials for sponsors.

In this interview, Patrice Matchaba, MD, President of Novartis US Foundation discusses how the biopharmaceutical industry can regain the trust of minorities.

Ken Getz, executive director and research professor at the Tufts Center for the Study of Drug Development, discusses the value of breakthrough findings with ROI and eNPV models.

Aasma Shaukat, MD, MPH, study co-lead, professor of medicine, and director of outcomes research for the Division of Gastroenterology and Hepatology at New York University Langone Health discusses how sites have evolved since COVID-19.

Melika Davis, SVP of Global Clinical Operations at BeiGene, discusses her perspectives on patient access, diversity, and risk mitigation.

Clinical data strategy and analytics, wearables and digital biomarkers, and risk-based quality management highlight notable takeaways.

In this article and video, Applied Clinical Trials blogger and Head of Research for CliniBiz Moe Alsumidaie, MBA, MSF, takes a deep dive into the reasons behind the CRA shortage and how industry can proactively address this problems.

Dr. Harish Dave, CEO of Singapore-based AUM Biosciences, discusses evolving strategies for Asian biopharmaceutical enterprises.

Craig Lipset, Co-Chair of DTRA, discusses the evolving nature of decentralized clinical trials and DTRA’s initiatives.

Mary Costello, Head of Site and Investigator Networks at Medable, and Stephanie Abbott, Clinical Research Director at Western Washington Medical Group, discuss the changing landscape of decentralized clinical trials.

The main themes discussed at DPHARM 2021.

Dave Hanaman, Co-founder of Curavit, discusses his perspectives on decentralized clinical trials.

Vanessa Tassell, Vice President of Clinical Operations at Mirati Therapeutics, will discuss how some enterprises are navigating trials by incorporating strategies to expand clinical trial access to patients who need it.

Dr. MaryAnne Rizk, Medable’s Chief Strategy Officer, discusses why sponsors are embracing the decentralized model more often and how it's solving issues like accessibility and diversity.

Nicole Richie, Global Head Health Equity and Population Science at Genentech/Roche, discusses a renewed strategy in big pharma to incorporate diversity inclusion in clinical trials.

Terence Rooney, VP of Clinical Development at Janssen, talks through the journey of how Janssen changed during the pandemic, and what the future holds.

Micki Hultquist, Vice President, Global Franchise Head at AstraZeneca, discusses the journey from a missed endpoint in TULIP-1 to a clinical success in TULIP-2

Thad Wolfram, President, Matrix Clinical Trials at Matrix Medical Network, speaks about his experience utilizing decentralization methodologies to increase clinical trial diversity inclusion by going deep into diverse communities.

Bari Kowal, Senior Vice President, Head Development Operations & Portfolio Management at Regeneron, discusses her experiences about how Regeneron rapidly and successfully developed a therapy to treat COVID-19.

Lan Fong, Founder and Principal Consultant at Avery Biopharma Consulting and Venture Partner at Congress Avenue Ventures, discusses her perspective on how the pandemic is shifting the clinical trials industry.